Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ciklentanilic acid
- Development stage
- Phase 2
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Ciklentanilic acid (CKBA) is a novel small molecule anti-inflammatory agent developed by West China Hospital, Sichuan University, for the topical treatment of inflammatory skin conditions, primarily papulopustular rosacea. It is characterized as a selective glucocorticoid receptor modulator (SEGRM) designed to provide potent anti-inflammatory activity similar to traditional corticosteroids but with a significantly improved safety profile, specifically aiming to avoid common steroid-induced side effects such as skin atrophy and telangiectasia. In addition to its effects on the glucocorticoid receptor, ciklentanilic acid has been shown to inhibit the activation of the NLRP3 inflammasome and downregulate the expression of pro-inflammatory cytokines such as IL-1β and TNF-α. It is currently being evaluated in Phase II clinical trials in China as a 1.5% cream formulation for patients with moderate to severe rosacea.
- Other names
- ciklentanilic acid
02
Targets
ACC (Acetyl-CoA Carboxylase 1)GR (Glucocorticoid receptor)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on ciklentanilic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ciklentanilic acid.